Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.

Clin Pharmacokinet · 2022 · PMC9287422 · PMID 35508594

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Additive Treatment Effects of Finerenone and SGLT2is While FIDELIO-DKD was not designed to demonstrate SGLT2i effects, finerenone but also SGLT2is showed strong and highly significant treatment effects on UACR and eGFR in FIDELIO-DKD.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.